Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer

被引：7
|
作者：
Huang, Linjuan [1 ,2 ,3 ,4 ]
Zhang, Jing [1 ,2 ,3 ,4 ]
Deng, Youling [1 ,2 ,3 ,4 ]
Wang, Hao [4 ,5 ,6 ]
Zhao, Piao [1 ,2 ,3 ,4 ]
Zhao, Guozhi [1 ,2 ,3 ,4 ]
Zeng, Wei [4 ,7 ]
Wang, Yonghui [4 ,8 ]
Chen, Connie [4 ]
Wagstaff, William [4 ]
Haydon, Rex C. [4 ]
Reid, Russell R. [4 ,9 ]
He, Tong-Chuan [4 ,10 ]
Shen, Le [4 ,10 ]
Luu, Hue H. [4 ]
Zhao, Ling [1 ,2 ,3 ,4 ]
机构：
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Chongqing 400046, Peoples R China
[2] Chongqing Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Chongqing 400046, Peoples R China
[3] Chongqing Med Univ, Affiliated Hosp 1, Dept Urol, Chongqing 400046, Peoples R China
[4] Univ Chicago, Med Ctr, Dept Orthopaed Surg & Rehabil Med, Mol Oncol Lab, Chicago, IL 60637 USA
[5] Chongqing Med Univ, Minist Educ, Sch Lab Med, Key Lab Diagnost Med, Chongqing 400016, Peoples R China
[6] Chongqing Med Univ, Sch Lab Med, Chongqing 400016, Peoples R China
[7] Jianghan Univ, Affiliated Hosp 2, Dept Neurol, Wuhan 430050, Hubei, Peoples R China
[8] Shanghai Jiao Tong Univ, Sch Med, Dept Clin Lab Med, Shanghai 200000, Peoples R China
[9] Univ Chicago, Med Ctr, Dept Surg Sect Plast Surg, Lab Craniofacial Suture Biol & Dev, Chicago, IL 60637 USA
[10] Univ Chicago, Med Ctr, Dept Surg, Chicago, IL 60637 USA
来源：
GENES & DISEASES | 2023年 / 10卷 / 04期
基金：
美国国家卫生研究院;
关键词：
Chemotherapy resistance; Cisplatin; Drug repurposing; Niclosamide; Ovarian cancer; MESENCHYMAL STEM-CELLS; BMP9-INDUCED OSTEOGENIC DIFFERENTIATION; SUPPRESSES TUMOR-GROWTH; WNT/BETA-CATENIN; ANTIHELMINTHIC NICLOSAMIDE; OSTEOBLAST DIFFERENTIATION; GENE-EXPRESSION; INHIBITION; PATHWAY; PROLIFERATION;
D O I：
10.1016/j.gendis.2022.12.005
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Ovarian cancer (OC) is one of the most lethal malignancies of the female reproduc-tive system. OC patients are usually diagnosed at advanced stages due to the lack of early diag-nosis. The standard treatment for OC includes a combination of debulking surgery and platinum-taxane chemotherapy, while several targeted therapies have recently been approved for maintenance treatment. The vast majority of OC patients relapse with chemoresistant tu-mors after an initial response. Thus, there is an unmet clinical need to develop new therapeu-tic agents to overcome the chemoresistance of OC. The anti-parasite agent niclosamide (NA) has been repurposed as an anti-cancer agent and exerts potent anti-cancer activities in human cancers including OC. Here, we investigated whether NA could be repurposed as a therapeutic
引用
收藏
页码：1687 / 1701
页数：15
相关论文
共 50 条
  • [41] Niclosamide Suppresses Proliferation, Induces Apoptosis and Inhibits Wnt/β-catenin Signaling Pathway in Human Ovarian Cancer Cells
    Gundogdu, Ayse Cakir
    Kaplanoglu, Gulnur Take
    Sivas, Hulya
    Varol, Reyhan
    Seymen, Cemile Merve
    GAZI MEDICAL JOURNAL, 2019, 30 (02): : 178 - 183
  • [42] Overcome of Cisplatin Resistance in Ovarian Cancer by Combination of Low-intensity Ultrasound and Cisplatin
    Kip, Bilgi
    Aydin, Omer
    CURRENT DRUG DELIVERY, 2023, 20 (09) : 1380 - 1390
  • [43] A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis
    Koenig, Philipp
    Zhulenko, Roman
    Suparman, Eloy
    Hoffmeister, Henrik
    Bueckreiss, Nico
    Ott, Ingo
    Bendas, Gerd
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 92 (01) : 57 - 69
  • [44] Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells
    Pfankuchen, Daniel Bastian
    Stoelting, Daniel Philipp
    Schlesinger, Martin
    Royer, Hans-Dieter
    Bendas, Gerd
    BIOCHEMICAL PHARMACOLOGY, 2015, 97 (02) : 147 - 157
  • [45] The cytoplasmic translocation of Cx32 mediates cisplatin resistance in ovarian cancer cells
    Wu, Weili
    Fan, Lixia
    Bao, Zeqing
    Zhang, Yu
    Peng, Yuexia
    Shao, Min
    Xiang, Yuke
    Zhang, Xiaomin
    Wang, Qin
    Tao, Liang
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 487 (02) : 292 - 299
  • [46] Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism
    Ai, Zhihong
    Lu, Yang
    Qiu, Songbo
    Fan, Zhen
    CANCER LETTERS, 2016, 373 (01) : 36 - 44
  • [47] Aspirin overcomes cisplatin resistance in lung cancer by inhibiting cancer cell stemness
    Zhao, Maoyuan
    Wang, Ting
    Hui, Zhouguang
    THORACIC CANCER, 2020, 11 (11) : 3117 - 3125
  • [48] p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins
    Yu, Huimei
    Su, Jing
    Xu, Ye
    Kang, Jinsong
    Li, Hongyan
    Zhang, Ling
    Yi, Haowei
    Xiang, Xiyan
    Liu, Fei
    Sun, Liankun
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (10) : 1585 - 1594
  • [49] PTEN overexpression improves cisplatin-resistance of human ovarian cancer cells through upregulating KRT10 expression
    Wu, Huijuan
    Wang, Ke
    Liu, Wenxin
    Hao, Quan
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2014, 444 (02) : 141 - 146
  • [50] Cancerous inhibitor of protein phosphatase 2A regulates cisplatin resistance in ovarian cancer
    Li, Wanbin
    Zhang, Hongyan
    Yang, Linqing
    Wang, Yunfei
    ONCOLOGY LETTERS, 2019, 17 (01) : 1211 - 1216
12345